Johnson & Johnson Invests $527,000 in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Johnson & Johnson bought a new stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the 4th quarter, HoldingsChannel reports. The firm bought 823,317 shares of the company’s stock, valued at approximately $527,000. Lyell Immunopharma makes up 0.1% of Johnson & Johnson’s portfolio, making the stock its 17th largest position.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC lifted its position in shares of Lyell Immunopharma by 716.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company’s stock worth $1,032,000 after purchasing an additional 1,414,746 shares in the last quarter. Takeda Pharmaceutical Co. Ltd. purchased a new position in Lyell Immunopharma in the 4th quarter valued at about $527,000. Charles Schwab Investment Management Inc. grew its stake in shares of Lyell Immunopharma by 43.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,645,787 shares of the company’s stock valued at $1,053,000 after acquiring an additional 498,417 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Lyell Immunopharma by 347.8% during the fourth quarter. JPMorgan Chase & Co. now owns 433,265 shares of the company’s stock worth $277,000 after acquiring an additional 336,516 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of Lyell Immunopharma by 312.7% in the third quarter. Barclays PLC now owns 240,615 shares of the company’s stock worth $332,000 after acquiring an additional 182,315 shares in the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Stock Performance

Shares of Lyell Immunopharma stock opened at $0.43 on Friday. Lyell Immunopharma, Inc. has a 1 year low of $0.39 and a 1 year high of $2.88. The firm’s 50-day simple moving average is $0.57 and its 200-day simple moving average is $0.76. The firm has a market cap of $128.01 million, a PE ratio of -0.55 and a beta of -0.26.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.01 million for the quarter. On average, equities analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a report on Wednesday.

Insiders Place Their Bets

In related news, CEO Lynn Seely purchased 175,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average price of $0.61 per share, with a total value of $106,750.00. Following the acquisition, the chief executive officer now owns 712,500 shares in the company, valued at approximately $434,625. This trade represents a 32.56 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard Klausner acquired 158,000 shares of Lyell Immunopharma stock in a transaction that occurred on Friday, March 14th. The shares were bought at an average price of $0.60 per share, with a total value of $94,800.00. Following the transaction, the director now directly owns 843,365 shares in the company, valued at approximately $506,019. This trade represents a 23.05 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 768,640 shares of company stock valued at $449,508 over the last 90 days. 25.10% of the stock is owned by company insiders.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.